Sabby Management’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Sabby Management’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-100,000	Closed	-$818K	–	375
2016 Q1	$818K	Sell	100,000 -777,342	-89%	-$5.86M	0.04%	171
2015 Q4	$7.79M	Buy	877,342 +702,399	+402%	+$7.3M	0.43%	40
2015 Q3	$1.69M	Buy	+174,943	New	+$2.46M	0.07%	179
2015 Q1	–	Sell	-95,839	Closed	-$788	–	343
2014 Q4	$788	Sell	95,839 -16,555	-15%	-$143K	0.02%	169
2014 Q3	$1.14K	Buy	112,394 +97,838	+672%	+$1.93M	0.04%	150
2014 Q2	$889K	Buy	+14,556	New	+$885K	0.04%	160

Other funds holding TBRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Sabby Management's TBRA Position: Q2 2016 in Review

Sabby Management sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2016, closing a stake of 100,000 shares — an estimated $818K sold.

Sabby Management first reported a position in TBRA in Q2 2014 and held it in 6 quarters. The position peaked at $7.79M in Q4 2015. 45 funds tracked by Wall St. Rank hold TBRA as of Q2 2016.

Sabby Management reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Sabby Management sold 100,000 Tobira Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $818K.
Sabby Management first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2014 and held it in 6 quarters.
Sabby Management's Tobira Therapeutics, Inc. Common Stock position peaked at $7.79M in Q4 2015.
45 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Sabby Management's 13F filing for Q2 2016, filed 15 Aug 2016.